Oyster Point Pharma, Inc. (OYST) [Rocket]

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-05-18	Dec-31-17
	10-K	10-K	10-K	10-K	8-K	S-1/A
Revenues [+]	24.5	0.0	0.0	0.0	13.8	3.6
Royalties					13.8	3.6
Revenue growth				-100.0%
Cost of goods sold	1.5	0.0	0.0	0.0	16.7	5.7
Gross profit	23.0	0.0	0.0	0.0	-3.0	-2.1
Gross margin	93.8%				-21.7%	-56.5%
Selling, general and administrative [+]	95.4	31.2	13.7	3.0	3.0	2.1
Sales and marketing	54.6	9.9
General and administrative	40.8	21.3	13.7	3.0	3.0	2.1
Research and development	24.2	39.8	33.6	13.8
Other operating expenses					10.8	1.6
EBITDA [+]	-96.5	-70.9	-47.3
EBITDA growth	36.1%	50.0%	182.5%	194.5%
EBITDA margin	-393.3%				-121.7%	-156.5%
Depreciation and amortization	0.1	0.1	0.0
EBIT [+]	-96.7	-71.0	-47.3	-16.7	-16.7	-5.7
EBIT growth	36.2%	50.1%	182.6%	194.5%
EBIT margin	-393.9%				-121.7%	-156.5%
Interest expense, net [+]	3.7		-1.6	-0.2	-0.2	0.0
Interest expense	3.7
Interest income			1.6	0.2	0.2	0.0
Other income (expense), net	-0.3	0.5			16.5	-13.5
Pre-tax income	-100.7	-70.5	-45.7	-16.5	0.0	-19.1
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%		0.0%
Net income	-100.7	-70.5	-45.7	-16.5	0.0	-19.1
Net margin	-410.2%				0.0%	-527.1%

Basic EPS [+]	($3.87)	($2.92)	($9.97)	($11.69)	$0.00	($13.56)
Growth	32.3%	-70.7%	-14.7%	-13.8%
Diluted EPS [+]	($3.87)	($2.92)	($9.97)	($11.69)	$0.00	($13.56)
Growth	32.3%	-70.7%	-14.7%	-13.8%

Shares outstanding (basic) [+]	26.0	24.1	4.6	1.4	1,412.0	1.4
Growth	7.9%	426.2%	224.7%	0.0%
Shares outstanding (diluted) [+]	26.0	24.1	4.6	1.4	1,412.0	1.4
Growth	7.9%	426.2%	224.7%	0.0%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.